Review article: Hepatitis C virus-related extra-hepatic disease - Aetiopathogenesis and management

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 2, 2004, Pages 129-141

  Medina, J ^a   Garcia Buey L ^a   Moreno Otero, R ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CD20 ANTIBODY; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; RITUXIMAB;

AGE DISTRIBUTION; ANEMIA; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CRYOGLOBULINEMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GLOMERULONEPHRITIS; GRAVES DISEASE; HASHIMOTO DISEASE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; IMMUNITY; IMMUNOCOMPETENT CELL; KIDNEY DISEASE; LICHEN PLANUS; LIVER DISEASE; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PETECHIA; PLASMAPHERESIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PURPURA; REVIEW; RHEUMATIC DISEASE; SENSITIZATION; SEX RATIO; SIALOADENITIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; THYROIDITIS; VASCULITIS; VIRUS INFECTION; XEROPHTHALMIA; XEROSTOMIA; HEMATOLOGIC DISEASE; SKIN DISEASE;

AUTOIMMUNE DISEASES; HEMATOLOGIC DISEASES; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES; NERVOUS SYSTEM DISEASES; SKIN DISEASES;

EID: 3242888585     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01919.x     Document Type: Review

References (112)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S21-9.
2. Manns MP, Rambusch E. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31(Suppl. 1): 39-42.
3. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79(1): 47-56.
4. Kayali Z, Buckwold V, Zimmerman B, Schmidt W. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002; 36(4 Part 1): 978-85.
5. Agnello V, Chung R, Kaplan L. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327(21): 1490-5.
6. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84(9): 3047-53.
7. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117(7): 573-7.
8. Pawlotsky JM, Yahia MB, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19(4): 841-8.
9. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106(5): 1291-300.
10. Ferri C, Zignego A, Pileri S. Cryoglobulins. J Clin Pathol 2002; 55(1): 4-13.
11. Ni J, Hembrador E, Bisceglie AD, et al. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 2003; 170(6): 3429-39.
12. Schott P, Hartmann H, Ramadori G. Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 2001; 16(4): 1275-85.
13. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330(11): 751-6.
14. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81(5): 1132-6.
15. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31(Suppl. 1): 210-6.
16. Buezo GF, Garcia-Buey M, Rios-Buceta L, Borque M, Aragues M, Dauden E. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis with hepatitis C virus infection. Int J Dermatol 1996; 35(2): 112-5.
17. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999; 13(9): 1179-86.
18. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282(5390): 938-41.
19. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137(7): 571-80.
20. Kitay-Cohen Y, Amiel A, Hilzenrat N, et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 2000; 96(8): 2910-2.
21. Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003; 102(4): 1196-201.
22. Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91(6): 2062-6.
23. Cacoub P, Renou C, Kerr G, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2001; 44(9): 2118-24.
24. Frankel AH, Singer D, Winearls C, Evans D, Rees A, Pusey C. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992; 82(298): 101-24.
25. Dammacco F, Sansonno D, Han J, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84(10): 3336-43.
26. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4): 778-89.
27. Casato M, Agnello V, Pucillo L, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90(10): 3865-73.
28. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27(9): 2172-8.
29. Cacoub P, Ratziu V, Myers R, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002; 36(6): 812-8.
30. Mazzaro C, Zorat F, Comar C, et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003; 30(8): 1775-81.
31. Sansonno D, Re VD, Lauletta G, Tucci F, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101(10): 3818-26.
32. Zaja F, Vita SD, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101(10): 3827-34.
33. Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 2001; 67(3): 168-71.
34. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87(10): 4296-301.
35. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102(3): 996-9.
36. Gisbert J, Garcia-Buey L, Pajares J, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma. Systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.
37. Rasul I, Shepherd F, Kamel-Reid S, Krajden M, Pantalony D, Heathcote E. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999; 29(2): 543-7.
38. Quinn ER, Chan C, Hadlock K, Foung S, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98(13): 3745-9.
39. Vallisa D, Berte R, Rocca A, et al. Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med 1999; 106(5): 556-60.
40. Tursi A, Brandimante G, Chiarelli F, Spagnoli A, Torello M. Detection of HCV RNA in gastric mucosa-associated lymphoid tissue by in situ hybridization: evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma. Am J Gastroenterol 2002; 97(7): 1802-6.
41. Hermine O, Lefrere F, Bronowicki J, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347(2): 89-94.
42. Kami M, Hamaki T, Murashige N, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J 2003; 4(2): 159-62.
43. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997; 92(1): 3-17.
44. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24(2): 135-40.
45. Pakula AS, Garden J, Roth S. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol 1993; 28(5 Part 2): 850-3.
46. DeCastro M, Sanchez J, Herrera J, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17(4): 551-7.
47. Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341(8848): 788-9.
48. Fargion S, Piperno A, Cappellini M, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16(6): 1322-6.
49. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27(6): 1661-9.
50. Murphy A, Dooley S, Hillary I, Murphy G. HCV infection in porphyria cutanea tarda. Lancet 1993; 341(8859): 1534-5.
51. Stolzel U, Kostler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21(6): 1500-3.
52. Carpintero P, DeCastro M, Garcia-Monzon C, et al. Hepatitis C virus infection detected by viral RNA analysis in porphyria cutanea tarda. J Infect 1997; 34(1): 61-4.
53. Gisbert JP, Garcia-Buey L, Pajares J, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39(4): 620-7.
54. Sheikh MY, Wright R, Burruss J. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alfa therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43(3): 529-33.
55. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22(2): 249-50.
56. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44(14): 525-8.
57. Furuta M, Kaito M, Gabazza E, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 2000; 35(1): 60-2.
58. Fernandez I, Castellano G, Salamanca RD, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003; 38(3): 314-9.
59. Jessner W, Der-Petrossian M, Christiansen L, et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002; 36(5): 1301-2.
60. Roy K, Bagg J. Hepatitis C virus and oral disease: a critical review. Oral Dis 1999; 5(4): 270-7.
61. Agnello V, Rosa FD. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-52.
62. Pilli M, Penna A, Zerbini A, et al. Oral lichen planus pathogenesis: a role for the HCV-specific cellular immune response. Hepatology 2002; 36(6): 1446-52.
63. Sanchez-Perez J, Moreno-Otero R, Borque M, Rios-Buceta L, Garcia-Diez A. Lichen planus and hepatitis C virus infection: a clinical and virologic study. Acta Derm Venereol 1998; 78(4): 305-6.
64. Tanei R, Watanabe K, Nishiyama S. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C. J Dermatol 1995; 22(5): 316-23.
65. Protzer U, Ochsendorf P, Leopolder-Ochsendorf A, Holtermuller K. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104(3): 903-5.
66. Johnson RJ, Gretch D, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328(7): 465-70.
67. Bandi L. Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent and thus overlooked. Postgrad Med 2003; 113(2): 73-6.
68. Davda R, Peterson J, Weiner R, Croker B, Lau J. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis 1993; 22(3): 452-5.
69. Yamabe H, Johnson R, Gretch D, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25(1): 67-9.
70. Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63(6): 2236-41.
71. Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113(6): 516-9.
72. Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14(6): 1558-60.
73. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001; 8(4): 287-92.
74. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18(8): 1573-80.
75. Martin P, Mitra S, Farrington K, Martin N, Modi M. Pegylated (40 KDa) interferon alfa-2a (Pegasys TM) is unaffected by renal impairment [abstract]. Hepatology 2000; 32(Part 2): 842.
76. Medina J, García-Buey L, Moreno-Monteagudo JA, Trapero-Marugán M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003; 60(2): 135-43.
77. Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36(1): 3-10.
78. Rostaing L, Chatelut E, Payen J, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9(12): 2344-8.
79. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21(3): 613-9.
80. Garcia-Carrasco M, Font-Franco J, Ingelmo-Morin M, Ramos-Casals M. Clinical manifestations and immunology associated with chronic infection with hepatitis C virus. Rev Clin Esp 2002; 202(4): 224-32.
81. Czaja AJ, Carpenter H, Santrach P, Moore S. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108(1): 157-64.
82. Medina J, Garcia-Buey L, Moreno-Otero R. Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther 2003; 17(1): 1-16.
83. Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37(3): 406-12.
84. Schiano TD, Te H, Thomas R, Hussain H, Bond K, Black M. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 2001; 96(10): 2984-91.
85. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116(1): 51-3.
86. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108(6): 1770-7.
87. Bortolotti F, Muratori L, Jara P, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003; 142(2): 185-90.
88. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123(1): 32-4.
89. Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21(2): 199-203.
90. Tran A, Quaranta J, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18(2): 253-7.
91. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321(22): 1506-10.
92. Lisker-Melman M, Bisceglie AD, Usala S, Weintraub B, Murray L, Hoofnagle J. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102(6): 2155-60.
93. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44(6): 635-42.
94. Deutsch M, Dourakis S, Manesis E, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26(1): 206-10.
95. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002; 25(7): 624-30.
96. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339(8789): 321-3.
97. Arrieta JJ, Rodriguez-Inigo E, Ortiz-Movilla N, et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158(1): 259-64.
98. De Re V, Vita SD, Gasparotto D, et al. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur J Immunol 2002; 32(3): 903-10.
99. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases. Medicine (Baltimore) 2001; 80(1): 1-8.
100. Heckmann JG, Kayser C, Heuss D, Manger B, Blum H, Neundorfer B. Neurological manifestations of chronic hepatitis C. J Neurol 1999; 246(6): 486-91.
101. Scelsa SN, Herskovitz S, Reichler B. Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle Nerve 1998; 21(11): 1526-9.
102. Ramos-Casals M, Trejo O, Garcia-Carrasco M, Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford) 2003; 42(7): 818-28.
103. Khella SL, Souayah N. Hepatitis C: a review of its neurologic complications. Neurology 2002; 8(2): 101-6.
104. Adinolfi LE, Utili R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997; 9(11): 1067-72.
105. Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1997; 27(1): 63-71.
106. Akriviadis EA, Xanthakis I, Navrozidou C, Papadopoulos A. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 1997; 25(4): 612-8.
107. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77(12); 2604-13.
108. Durand JM, Cacoub P, Lunel-Fabiani F, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998; 25(6): 1115-7.
109. Safadi R, Shouval D, Kaspa R, Ashur Y, Ilan Y. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. Liver Transpl Surg 1996; 2(4): 263-8.
110. Lamprecht P, Gause A, Gross W. Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. Scand J Rheumatol 2000; 29(3): 201-2.
111. Cacoub P, Maisonobe T, Thibault V, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001; 28(1): 109-18.
112. Stehman-Breen C, Alpers C, Couser W, Willson R, Johnson R. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44(3): 141-7.